Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04535986 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
A Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 763
- Enrollment target
- 20
- Study locations
NCT04535986 is a Phase 3 study of Chronic Obstructive Pulmonary Disease that has completed, run by Verona Pharma. The registered enrollment target is 763 participants, below the 1,745-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04535986, a Phase 3 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Verona Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 763 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ensifentrine
Study Locations (20)
Florida
- Clinical Research of West Florida, Inc. - Clearwater
- St. Francis Medical Institute - Clearwater
- Qway Research, LLC - Hialeah
- Multi-Specialty Research Associates, Inc. - Lake City
- Elite Clinical Research - Miami
- Global Research Solutions Corp - Miami
- Phoenix Medical Research - Miami
- Florida Institute for Clinical Research - Orlando
- Precision Clinical Research - Sunrise
- Clinical Research of West Florida, Inc. - Tampa
Georgia
- iResearch Atlanta, LLC - Decatur
- IACT Health - Rincon
- In-Quest Medical Research, LLC - Suwanee
Arizona
- Phoenix Medical Group - Peoria
- AMR Tempe - Tempe
California
- Beach Physicians Medical Group - Huntington Beach
- Downtown LA Research Center, Inc. - Los Angeles
Maryland
- John Hopkins University School of Medicine - Baltimore
Michigan
- Pulmonary Research Institute of SE Michigan - Farmington Hills
Missouri
- Midwest Chest Consultants - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 763 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2022-12-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04535986
The ClinicalTrials.gov registry entry for NCT04535986 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 763 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,745-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (56% lower). The listed sponsor is Verona Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04535986 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Georgia, Arizona.
Frequently Asked Questions
What is clinical trial NCT04535986 about?
NCT04535986 is a clinical study titled "A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD". The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
What is the current status of trial NCT04535986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 763 participants. The study started on 2020-09-29. Estimated completion is 2022-12-02.
What conditions does trial NCT04535986 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT04535986?
The interventions under investigation include: Placebo (DRUG), Ensifentrine (DRUG).
Who is sponsoring clinical trial NCT04535986?
This trial is sponsored by Verona Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04535986 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.